Mark Egerton Appointed Chairman of Panthera Biopartners

Mark Egerton Appointed Chairman of Panthera Biopartners

Panthera Biopartners, the UK’s leading Site Management Organisation (SMO) which runs commercial clinical trials for the pharmaceutical industry, has appointed Mark Egerton as Chairman.

Mark brings extensive experience in the pharmaceutical industry across the UK and the US. He is currently Chairman of Newmarket Strategy and was previously CEO of Quotient Sciences, where he oversaw significant growth and international expansion.

Commenting on his appointment, Mark said, “I am delighted to join the board of Panthera Biopartners. The management team has done an exceptional job in building the UK’s most successful SMO in only five years and is already working with ten of the top twelve pharmaceutical companies and seven of the top CROs. With the backing of LDC and BGF, Panthera will now seek to further expand its operations in the UK and Europe”.

Panthera Biopartners was founded in 2019 and has rapidly become a key partner for global pharmaceutical and biotech companies, supporting faster and more efficient patient recruitment across a growing network of dedicated clinical trial sites.

ENDS

For media information:

Simon Vane Percy / Kerry Saunders
Vane Percy & Roberts
(t) +44(0)7710 005 910 / +44(0)7342 962 761
(e) simon@vanepercy.com / (e) kerry@vanepercy.com

About Panthera:

Panthera is the UK’s largest Site Management Organisation (SMO) that recruits patients and runs clinical trials at six dedicated clinical trial clinics across the UK on behalf of its clients - CROs and pharma.  Since launching in 2019, Panthera has continued to refine the SMO model and has quickly grown to be number one in the UK. In 2024, Panthera was the top global recruiter in four international clinical studies and had the first patient recruited in nine trials globally or within the UK.

For more information visit Home Page - Panthera Clinical Trials

​